Fiche du document
2013
- doi: 10.1371/journal.pntd.0002134
- issn: 1935-2727
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1371/journal.pntd.0002134
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/23556019
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1935-2735
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_EFA9E03DEF245
info:eu-repo/semantics/openAccess , Copying allowed only for non-profit organizations , https://serval.unil.ch/disclaimer
Sujets proches
Therapy Assam fever Dumdum fever Visceral leishmaniasis Immune depression Immune suppression Suppression, Immune Depression, Immune ImmunodepressionCiter ce document
T. Abebe et al., « Arginase activity - a marker of disease status in patients with visceral leishmaniasis in ethiopia. », Serveur académique Lausannois, ID : 10.1371/journal.pntd.0002134
Métriques
Partage / Export
Résumé
The underlying mechanisms resulting in the profound immune suppression characteristic of human visceral leishmaniasis (VL) are not fully understood. Here, we tested the hypothesis that arginase, an enzyme associated with immunosuppression, is higher in patients with VL and contributes to impaired T cell responses. We recruited patients with VL before and after treatment and healthy controls and measured the arginase metabolism in the blood of these individuals. Our results show that arginase activity is significantly higher in the blood of patients with active VL as compared to controls. These high levels of arginase decline considerably once the patients are successfully treated. We identified the phenotype of arginase-expressing cells among PBMCs as neutrophils and show that their frequency was increased in PBMCs of patients before treatment; this coincides with reduced levels of L-arginine in the plasma and decreased expression levels of CD3ζ in T cells.